The leading causes of death in these patients with T2D are cardiovascular diseases and cancer due to their pathogenesis being aggravated by metabolic syndrome [2]
Its role as a hepatocyte growth promoter further expands its therapeutic applications, as hepatocyte growth factors are critical in tissue repair and regeneration
Neither cagrilintide nor retatrutide is currently licensed in the UK, so neither is available through NHS or private prescribing routes
A safe stopping point means you have successfully tapered to the lowest dose or off the medication entirely, while maintaining weight stability, normal appetite signaling, and stable blood sugar control over at least 48 weeks post-discontinuation
Never had I been so sedentary as I was at the start of the pandemic, when my work called me to sit in front of a computer for often 12 hours a day
doi: 10.1038/s41467-021-22033-2 3 BalabanN.CirioniO.GiacomettiA.GhiselliR.BraunsteinJ